Loading
A phase 3 trial of Eribulin, Capecitabine, Gemcitabine and Vinorelbine in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT06081959 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 376 participants planned, started 2023-10-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: SKB264, Eribulin, Capecitabine, Gemcitabine and Vinorelbine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Sichuan Kelun-Biotech, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Eribulin, Capecitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Kelun-Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/